ãã€ãªå»è¬åäŒç€Ÿã§ããAmpio Pharmaceuticals, Inc.ã¯ãç±³åœã§èå»¶ããŠããççæ§çŸæ£ã®æ²»çã®ããã®å
ç«åŠã«åºã¥ãæ²»çæ³ã®éçºã«æ³šåããŠããŸããå瀟ã®è£œåãã€ãã©ã€ã³ã«ã¯ãèã®å€åœ¢æ§é¢ç¯çã®æ²»çã®ããã®ç¬¬3çžèšåºè©Šéšäžã®é¢ç¯å
泚å°å€AP-013ãåŒåžåšçŸæ£ãæ£ãCOVID-19æ£è
ã®ããã®ç¬¬I/IIçžèšåºè©Šéšäžã®éèå
æ²»çå€AP-016ãCOVID-19èªçºæ§åŒåžå°é£ã®ããã®ç¬¬Içžèšåºè©Šéšäžã®åžå
¥æ²»çå€AP-014ãªã©ããããŸããå瀟ã¯ã³ãã©ãå·ã€ã³ã°ã«ãŠããã«æ¬ç€Ÿã眮ããŠããŸãã